Physician profile
Haijun Yao
NPI 1972135374
$1,773.57
in general payments reported to CMS, 2019-2025
22 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $253 · 2024: $420 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $308.93 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $255.17 | 2023-2025 | Lokelma, Farxiga, Breztri |
| Novo Nordisk INC | $250.17 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Shield Therapeutics INC | $148.71 | 2024-2025 | |
| Exact Sciences Corporation | $119.68 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $110.27 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $86.21 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $84.60 | 2024-2025 | |
| Boston Scientific Corporation | $54.59 | 2025 | Watchman Flx |
| Insulet Corporation | $45.48 | 2024-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $40.11 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.00 | 2025 | Caplyta |
| Mimedx Group, INC. | $31.07 | 2025 | |
| Amgen INC. | $29.46 | 2024-2025 | Repatha, Repatha, Otezla |
| Sequel Med Tech, LLC | $27.90 | 2025 | Twiist |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27.19 | 2024 | Voquezna |
| Hologic Sales and Service, LLC | $24.70 | 2025 | Aptima |
| Ipsen Biopharmaceuticals, INC | $21.72 | 2025 | Dysport |
| Ibsa Pharma INC. | $19.96 | 2024 | Flector, Licart, Tirosint |
| Pharming Healthcare, INC. | $19.42 | 2025 | Ruconest |
| Abbott Laboratories | $19.24 | 2025 | Freestyle Libre 3 |
| Cepheid | $14.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haijun Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.